Barclays analyst Luke Sergott lowered the firm’s price target on Catalent to $58 from $62 and keeps an Overweight rating on the shares. The analyst says 2023 will likely be a "tale of 2 cities" for traditional tools verses bioprocessing names. The year likely favors conservative management teams with a history of beating estimates, the firm tells investors in a research note.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on CTLT:
- Catalent appoints Zayas as SVP, Operations, Biologics North America
- Johnson & Johnson cuts production of Covid-19 vaccine, WSJ reports
- Early notable gainers among liquid option names on January 11th
- Avantor, Catalent enter multi-year supply agreement
- Acorda Therapeutics enters new long-term supply pact with Catalent on INBRIJA
